<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; SPA</title>
	<atom:link href="http://www.stockbloghub.com/tag/spa/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SPPI) Spectrum Pharmaceuticals to Continue Cancer Study</title>
		<link>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649</link>
		<comments>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649#comments</comments>
		<pubDate>Fri, 08 Apr 2011 17:19:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics Inc.]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[DMC]]></category>
		<category><![CDATA[Document Security Systems Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals Inc.]]></category>
		<category><![CDATA[SPPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70649</guid>
		<description><![CDATA[Recently, Spectrum Pharmaceuticals Inc. (SPPI) announced that it will continue evaluating its cancer candidate belinostat based on the recommendation of the independent Data Monitoring Committee (DMC). Spectrum Pharma is currently studying belinostat for treating patients suffering from relapsed or refractory peripheral T-Cell lymphoma (PTCL) in a phase II pivotal trial (BELIEF). Spectrum Pharma is evaluating belinostat as a monotherapy in the study. The committee conducted a safety and futility analysis of the interim data from the study before recommending its continuation until 100 evaluable subjects are enrolled. Spectrum Pharma is conducting the study under a Special Protocol Assessment (SPA) with the US Food and Drug Administration (FDA). Spectrum Pharma intends to seek approval of belinostat from the FDA in 2011/2012. We believe that if belinostat is successfully developed and commercialized ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/08/sppi-spectrum-pharmaceuticals-to-continue-cancer-study/70649/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Loss Smaller Than Forecast &#8211; Revenues Strong</title>
		<link>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408</link>
		<comments>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408#comments</comments>
		<pubDate>Mon, 15 Nov 2010 22:14:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59408</guid>
		<description><![CDATA[Incyte Corporation (INCY) suffered a loss of 26 cents per share in the third quarter of 2010. Loss in the reported quarter was narrower than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago loss (excluding special items) of 39 cents per share. The strong performance in the quarter was attributable to a surge in revenues. Total revenues in the reported quarter jumped to $16.9 million from $939,000 in the year-ago quarter. Revenues were boosted by the receipt of $16.7 million in milestone payments from partners Novartis (NVS) and Eli Lilly &#38; Co. (LLY).  Revenues were in line with the Zacks Consensus Estimate. Total cost and expenses in the reported quarter climbed 19.8% to $38.9 million. Both research and development (R&#38;D) expenses (up 15.4%) and selling, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceuticals Industries Oncology Drug Progresses</title>
		<link>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966</link>
		<comments>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966#comments</comments>
		<pubDate>Wed, 06 Oct 2010 03:45:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53966</guid>
		<description><![CDATA[Teva Pharmaceuticals Industries Ltd. (TEVA) and OncoGenex Pharmaceuticals, Inc. (OXGI) recently announced that they have initiated a second phase III study with their oncology candidate, custirsen (OGX-011/TV-1011). The trial, SYNERGY, will evaluate custirsen as a first-line treatment for patients suffering from metastatic castrate-resistant prostate cancer (CRPC). The controlled global study will be conducted with about 800 men who will be randomized to receive either docetaxel/prednisone plus custirsen or just docetaxel/prednisone. The primary endpoint is overall survival benefit. Custirsen is already in another phase III study that was initiated in June 2010. This study, SATURN, is evaluating custirsen as a second-line therapy in patients with metastatic CRPC. Both phase III studies are being conducted under the US Food and Drug Administration’s (FDA) Special Protocol Assessment (SPA) program. Custirsen enjoys fast track ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KERX) Keryx Biopharmaceuticals Earns FDA Fast Track Status</title>
		<link>http://www.stockbloghub.com/2010/04/07/kerx-keryx-biopharmaceuticals-earns-fda-fast-track-status/33034</link>
		<comments>http://www.stockbloghub.com/2010/04/07/kerx-keryx-biopharmaceuticals-earns-fda-fast-track-status/33034#comments</comments>
		<pubDate>Wed, 07 Apr 2010 23:53:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33034</guid>
		<description><![CDATA[Keryx Biopharmaceuticals (KERX) received fast track status from the US Food and Drug Administration (FDA) for KRX-0401 (perifosine), which is being studied for treating refractory advanced colorectal cancer. This status is granted to drugs with the potential to treat serious or fatal conditions and qualify for a faster review process. Keryx plans to initiate a phase III trial of perifosine in the second quarter of 2010 under the FDA’s Special Protocol Assessment (SPA) program. The trial aims at comparing perifosine in combination with capecitabine (Xeloda) versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. The study is expected to be completed in the second half of 2011. Keryx plans to launch the drug by mid 2012. Although perifosine is the lead candidate at Keryx, it is also developing Zerenex ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/kerx-keryx-biopharmaceuticals-earns-fda-fast-track-status/33034/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(POZN) Pozen Initiates New Phase III Trial</title>
		<link>http://www.stockbloghub.com/2009/11/20/pozn-pozen-initiates-new-phase-iii-trial/21047</link>
		<comments>http://www.stockbloghub.com/2009/11/20/pozn-pozen-initiates-new-phase-iii-trial/21047#comments</comments>
		<pubDate>Fri, 20 Nov 2009 23:29:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21047</guid>
		<description><![CDATA[This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. FDA, and one long-term safety study. The two pivotal programs will enroll approximately 500 patients per study at over 100 sites around the U.S. The primary endpoint of the pivotal studies is the cumulative incidence of gastric ulcers over the six-month treatment period for PA32540 versus 325 mg of enteric-coated aspirin. The long-term study will enroll approximately 400 patients and assess safety over a period of one year. Pozen is developing PA-325/40 for use in the secondary prevention of heart attacks and strokes in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/20/pozn-pozen-initiates-new-phase-iii-trial/21047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

